As President, Chief Executive Officer, and board director, Nancy Lurker leads EyePoint Pharmaceuticals in its mission to improve the lives of people facing serious eye disorders. During her more than 30 years in the pharmaceutical industry, Ms. Lurker has driven scientific and commercial innovation, working with both public and private companies from startups to the Fortune 500 to bring innovative therapies and diagnostic solutions to patients. Prior to joining EyePoint in 2016, Ms. Lurker was President, CEO, and board director of PDI, Inc., a NASDAQ-listed healthcare commercialization company that was sold to Publicis Health. Before joining PDI, she was senior vice president and Chief Marketing Officer at Novartis Pharmaceuticals. She also served as President and CEO of ImpactRx, Inc., a privately held healthcare information company. Prior to ImpactRx, Ms. Lurker was group VP, global primary care products for Pharmacia Corporation, and a member of Pharmacia’s U.S. Executive Management Committee. She began her career as a senior medical representative at Bristol Myers Squibb, where she quickly rose to senior director of worldwide cardiovascular franchise management, overseeing numerous successful drug launches. Ms. Lurker currently serves on the board of directors of Eyepoint Pharmaceuticals, Altasciences, and Aquestive Therapeutics and as a member of the Novo Holdings Advisory Board. She was recognized in Healthcare Technology Report’s Top 25 Women Leaders in Medical Devices in 2022 and as one of the most inspiring people in the life sciences industry on the 2022 PharmaVoice 100 list. She has previously held positions on the boards of Cancer Treatment Centers of America, Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals, PDI, Elan Pharmaceuticals, Conjuchem, and ImpactRx. Ms. Lurker holds a BS in biology from Seattle Pacific University and an MBA from the University of Evansville. Dedicating her career to maximizing the potential of science to improve the lives of patients, Ms. Lurker is passionate about supporting the future of STEM and engaging with the critical thinkers and innovators of tomorrow.
